A
Abcuro
The next generation of T cell targeted bio-therapeutics
About Abcuro
Abcuro, Inc. is a biotechnology company focused on developing advanced immunotherapies to treat autoimmune diseases and cancer. The company operates in the biopharmaceutical market, specifically targeting dysfunctional immune pathways to create novel therapies. Abcuro takes a patient-centric approach, identifying and validating the role of these pathways in various diseases to discover new treatments. The company primarily serves patients suffering from autoimmune conditions and certain types of cancer. Abcuro's business model revolves around research and development, with revenue generated through partnerships, grants, and potential future sales of their proprietary therapies. The company is headquartered in Newton, MA, and is led by a team of experienced scientists and medical professionals. Key areas of focus include the role of KLRG1 T cells in diseases like Primary Biliary Cholangitis and Inclusion Body Myositis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Newton, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 65.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2025 | $200M | $800M | Redmile Group · RA Capital Management · Samsara BioCapital · Bain Capital Life Sciences | ↗ |
| SERIES BOther financing | Aug 2023 | $155M | $620M | Tekla Capital Management · Pontifax Funds · Redmile Group · Samsara BioCapital | ↗ |
Growth signals
Latest recorded traffic for Abcuro is 2.5K monthly website visits, down 21.9% over the last three months. Abcuro's team declined 27.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Sanofi Ventures
RA Capital Management
Samsara BioCapital- TMTekla Capital Management
Pontifax Funds
Redmile Group
Bain Capital Life Sciences
Eurofarma
New Leaf Ventures
BlackRock- SCSoleus Capital
Mass General Brigham Ventures
Series B and later2 investors entered at this stage
Other known investors2 additional known investors
Brigham and Women's Hospital
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abcuro on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abcuro’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.